Improved Alzheimer's Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study.

Autor:	Laton J; AIMS, Center for Neurosciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium.; Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK., Van Schependom J; AIMS, Center for Neurosciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium.; Department of Electronics and Informatics (ETRO), Vrije Universiteit Brussel, Brussels, Belgium., Goossens J; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.; Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., Wiels W; Neuroprotection and Neuromodulation (NEUR), Center for Neurosciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium.; Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Sieben A; Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., De Deyn PP; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.; Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.; Alzheimer Center Groningen, University of Groningen and University Medical Center Groningen (UMCG), Groningen, The Netherlands., Goeman J; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium., Streffer J; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.; AC Immune SA, Lausanne, Switzerland., van der Zee J; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.; Neurodegenerative Brain Diseases, VIB Center for Molecular Neurology, Edegem, Belgium., Martin JJ; Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., Van Broeckhoven C; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.; Neurodegenerative Brain Diseases, VIB Center for Molecular Neurology, Edegem, Belgium., De Vos M; ESAT - Department of Electrical Engineering and Department of Development & Regeneration, KU Leuven, Leuven, Belgium.; Department of Engineering Science, Institute of Biomedical Engineering, University of Oxford, Oxford, UK., Bjerke M; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.; Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.; Neuroprotection and Neuromodulation (NEUR), Center for Neurosciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium.; Laboratory of Neurochemistry, Universitair Ziekenhuis Brussel, Brussels, Belgium., Nagels G; AIMS, Center for Neurosciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium.; Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium.; Department of Engineering Science, Institute of Biomedical Engineering, University of Oxford, Oxford, UK.; St Edmund Hall, University of Oxford, Oxford, UK., Engelborghs S; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.; Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.; Neuroprotection and Neuromodulation (NEUR), Center for Neurosciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium.; Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Jazyk:	angličtina
Zdroj:	Journal of Alzheimer's disease : JAD [J Alzheimers Dis] 2022; Vol. 90 (4), pp. 1739-1747.
DOI:	10.3233/JAD-220693
Abstrakt:	Background: Distinguishing between Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) results in poor diagnostic accuracy. Objective: To investigate the utility of electroencephalography (EEG)-based biomarkers in comparison and in addition to established cerebrospinal fluid (CSF) biomarkers in the AD versus FTLD differential diagnosis. Methods: The study cohort comprised 37 AD and 30 FTLD patients, of which 17 AD and 9 FTLD patients had definite diagnoses. All participants had CSF neurochemical (NCM) biomarker analyses (Aβ1-42, T-tau, P-tau181, and Nf-L) and underwent 19-channel resting-state EEG. From the EEG spectra, dominant frequency peaks were extracted in four regions resulting in four dominant frequencies. This produced eight features (4 NCM + 4 EEG). Results: When NCM and EEG markers were combined, the diagnostic accuracy increased significantly. In the whole group, the accuracy went up from 79% (NCM) to almost 82%, while in the definite group only, it went up from around 85% to almost 95%. Two differences in the occurrence of the dominant EEG frequency were discovered: people lacking a clear dominant peak almost all had definite AD, while people with two peaks more often had FTLD. Conclusion: Combining EEG with NCM biomarkers resulted in differential diagnostic accuracies of 82% in clinically diagnosed AD and FTD patients and of 95% in patients having a definite diagnosis, which was significantly better than with EEG or NCM biomarkers alone. This suggests that NCM and EEG markers are complementary, revealing different aspects of the disease and therefore confirms again their relevance in developing additional diagnosis tools.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu